A. Loyse

发表

Healthcare Costs and Life-years Gained From Treatments Within the Advancing Cryptococcal Meningitis Treatment for Africa (ACTA) Trial on Cryptococcal Meningitis: A Comparison of Antifungal Induction Strategies in Sub-Saharan Africa

S. Jaffar, R. Heyderman, A. Gheorghe, 2019, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Health care costs and life years gained from treatments within the ACTA trial on cryptococcal meningitis : a comparison of antifungal induction strategies in sub Saharan Africa

Griffiths, R. Heyderman, A. Gheorghe, 2018 .

Drug resistant TB: UK multicentre study (DRUMS): Treatment, management and outcomes in London and West Midlands 2008-2014.

G. Cooke, P. Butcher, T. Harrison, 2017, The Journal of infection.

Multidrug-resistant tuberculosis (MDR-TB) treatment in the UK: a study of injectable use and toxicity in practice.

G. Cooke, T. Harrison, O. Kon, 2011, The Journal of antimicrobial chemotherapy.

Early Clinical and Subclinical Visual Evoked Potential and Humphrey's Visual Field Defects in Cryptococcal Meningitis

C. Connolly, T. Harrison, A. Bhigjee, 2012, PloS one.

Cryptococcal antigen in serum and cerebrospinal fluid for detecting cryptococcal meningitis in adults living with HIV: systematic review and meta-analysis of diagnostic test accuracy studies.

Jérémie F. Cohen, J. Perfect, T. Harrison, 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Positive predictive value of the UK clinical case definition for H1N1/09 ('swine') influenza.

T. Harrison, M. Wansbrough-Jones, A. Solomon, 2010, The Journal of infection.

Genome-Wide Association Study Identifies Novel Colony Stimulating Factor 1 Locus Conferring Susceptibility to Cryptococcosis in Human Immunodeficiency Virus-Infected South Africans

C. Wijmenga, M. Netea, A. Pittman, 2020, Open forum infectious diseases.

Methods : An open-label phase III randomised controlled non-inferiority trial conducted in five countries in sub-Saharan Africa

Duolao Wang, S. Jaffar, D. Boulware, 2019 .

Cryptococcal Antigen Screening in Asymptomatic HIV-Infected Antiretroviral Naïve Patients in Cameroon and Evaluation of the New Semi-Quantitative Biosynex CryptoPS Test

E. Delaporte, F. Dromer, T. Harrison, 2018, Front. Microbiol..

AMBIsome Therapy Induction OptimisatioN (AMBITION): High Dose AmBisome for Cryptococcal Meningitis Induction Therapy in sub-Saharan Africa: Study Protocol for a Phase 3 Randomised Controlled Non-Inferiority Trial

Duolao Wang, S. Jaffar, D. Boulware, 2018, Trials.

Long-term Mortality and Disability in Cryptococcal Meningitis: A Systematic Literature Review

T. Harrison, O. Lortholary, S. Molloy, 2017, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Starting ART following cryptococcal meningitis : the optimal time has yet to be defined : forum

J. Jarvis, T. Harrison, T. Bicanic, 2013 .

Flucytosine and cryptococcosis: time to urgently address the worldwide accessibility of a 50-year-old antifungal

F. Dromer, T. Harrison, J. Day, 2013, The Journal of antimicrobial chemotherapy.

Cryptococcal Antigen in Serum and Cerebrospinal Fluid for Detecting Cryptococcal Meningitis in Adults Living With Human Immunodeficiency Virus: Systematic Review and Meta-Analysis of Diagnostic Test Accuracy Studies

J. Perfect, T. Chiller, O. Lortholary, 2021 .

High-dose amphotericin B with flucytosine for the treatment of cryptococcal meningitis in HIV-infected patients: a randomized trial.

S. Jaffar, L. Bekker, R. Wood, 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Antifungal Combinations for Treatment of Cryptococcal Meningitis in Africa

Duolao Wang, S. Jaffar, R. Heyderman, 2018, The New England journal of medicine.

Supplementary Results

R. Wood, N. White, C. Bottomley, 2013 .

Effect of oral fluconazole 1200 mg/day on QT interval in African adults with HIV-associated cryptococcal meningitis

R. Heyderman, Chimwemwe Chawinga, T. Harrison, 2018, AIDS.

Efficient phagocytosis and laccase activity affect the outcome of HIV-associated cryptococcosis.

M. Fisher, R. May, J. Jarvis, 2014, The Journal of clinical investigation.

Very Low Levels of 25-Hydroxyvitamin D Are Not Associated With Immunologic Changes or Clinical Outcome in South African Patients With HIV-Associated Cryptococcal Meningitis

J. Perfect, J. Jarvis, G. Meintjes, 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Comparison of the early fungicidal activity of high-dose fluconazole, voriconazole, and flucytosine as second-line drugs given in combination with amphotericin B for the treatment of HIV-associated cryptococcal meningitis.

S. Jaffar, L. Bekker, R. Wood, 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Determinants of Mortality in a Combined Cohort of 501 Patients With HIV-Associated Cryptococcal Meningitis: Implications for Improving Outcomes

S. Jaffar, R. Wood, N. White, 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Neurological, visual, and MRI brain scan findings in 87 South African patients with HIV-associated cryptococcal meningoencephalitis.

T. Harrison, D. Wilson, A. Bhigjee, 2015, The Journal of infection.

New Insights Into Cryptococcus Spp. Biology and Cryptococcal Meningitis

O. Lortholary, A. Alanio, F. Lanternier, 2019, Current Neurology and Neuroscience Reports.

Cryptococcal meningoencephalitis: time for action.

J. Perfect, D. Lalloo, J. Jarvis, 2021, The Lancet. Infectious diseases.

Cryptococcal meningitis: improving access to essential antifungal medicines in resource-poor countries.

N. Ford, P. Easterbrook, T. Harrison, 2013, The Lancet. Infectious diseases.

Global burden of disease of HIV-associated cryptococcal meningitis: an updated analysis.

D. Boulware, D. Denning, Benjamin J Park, 2017, The Lancet. Infectious diseases.

Cryptococcal meningitis: epidemiology, immunology, diagnosis and therapy

M. Fisher, P. Williamson, J. Jarvis, 2017, Nature Reviews Neurology.

Independent association between rate of clearance of infection and clinical outcome of HIV-associated cryptococcal meningitis: analysis of a combined cohort of 262 patients.

S. Jaffar, L. Bekker, R. Wood, 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Time to embrace access programmes for medicines: Lessons from the South African flucytosine access programme.

G. Meintjes, T. Harrison, N. Govender, 2020, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

AMBIsome Therapy Induction OptimisatioN (AMBITION): High dose AmBisome for cryptococcal meningitis induction therapy in sub-Saharan Africa: economic evaluation protocol for a randomised controlled trial-based equivalence study

Duolao Wang, S. Jaffar, D. Boulware, 2019, BMJ Open.

Leave no one behind: response to new evidence and guidelines for the management of cryptococcal meningitis in low-income and middle-income countries.

N. Ford, S. Jaffar, J. Klausner, 2019, The Lancet. Infectious diseases.

Addition of Flucytosine to Fluconazole for the Treatment of Cryptococcal Meningitis in Africa: A Multicountry Cost-effectiveness Analysis

S. Jaffar, R. Heyderman, L. Niessen, 2019, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

High ongoing burden of cryptococcal disease in Africa despite antiretroviral roll out.

J. Jarvis, G. Meintjes, T. Harrison, 2009, AIDS.

Histopathology of the arachnoid granulations and brain in HIV-associated cryptococcal meningitis: correlation with cerebrospinal fluid pressure

J. Jarvis, G. Meintjes, T. Harrison, 2010, AIDS.

Relationship of cerebrospinal fluid pressure, fungal burden and outcome in patients with cryptococcal meningitis undergoing serial lumbar punctures

S. Jaffar, R. Wood, N. White, 2009, AIDS.

British HIV Association opportunistic infection guidelines: in defence of amphotericin B deoxycholate

T. Bicanic, L. Whitney, A. Loyse, 2012, HIV medicine.

Cryptococcal meningitis: A neglected NTD?

Shabbar Jaffar, David R Boulware, S. Jaffar, 2017, PLoS neglected tropical diseases.

The global burden of HIV-associated cryptococcal infection in adults in 2020: a modelling analysis.

D. Boulware, D. Denning, N. Govender, 2022, The Lancet. Infectious diseases.

Establishing targets for advanced HIV disease: A call to action

D. Boulware, J. Jarvis, T. Harrison, 2021, Southern African journal of HIV medicine.

Short-term Mortality Outcomes of HIV-Associated Cryptococcal Meningitis in Antiretroviral Therapy–Naïve and –Experienced Patients in Sub-Saharan Africa

Duolao Wang, S. Jaffar, R. Heyderman, 2021, Open forum infectious diseases.

Pseudomonas stutzeri pneumonia in an HIV seropositive patient.

A. Loyse, R. Storring, M. Melzer, 2006, The Journal of infection.

Transcriptional Profiling of Patient Isolates Identifies a Novel TOR/Starvation Regulatory Pathway in Cryptococcal Virulence

T. Myers, P. Gardina, J. Qiu, 2018, mBio.

Transcriptional Profiling of Patient Isolates Identifies a Novel TOR Regulatory Pathway in Cryptococcal Virulence

T. Myers, P. Gardina, J. Qiu, 2018, bioRxiv.

One-year Mortality Outcomes From the Advancing Cryptococcal Meningitis Treatment for Africa Trial of Cryptococcal Meningitis Treatment in Malawi

S. Jaffar, R. Heyderman, Chimwemwe Chawinga, 2019, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Immune Reconstitution Inflammatory Syndrome in HIV-Associated Cryptococcal Meningitis: A Prospective Study

Shabbar Jaffar, S. Jaffar, R. Wood, 2009, Journal of acquired immune deficiency syndromes.

Genotypic Diversity Is Associated with Clinical Outcome and Phenotype in Cryptococcal Meningitis across Southern Africa

S. O'Hanlon, M. Fisher, R. May, 2015, PLoS neglected tropical diseases.

Cost-effectiveness of single, high-dose, liposomal amphotericin regimen for HIV-associated cryptococcal meningitis in five countries in sub-Saharan Africa: an economic analysis of the AMBITION-cm trial.

Takudzwa J Mtisi, S. Jaffar, D. Boulware, 2022, The Lancet. Global health.

Single-Dose Liposomal Amphotericin B Treatment for Cryptococcal Meningitis

Duolao Wang, S. Jaffar, D. Boulware, 2022, The New England journal of medicine.

Correction to: AMBIsome Therapy Induction OptimisatioN (AMBITION): High Dose AmBisome for Cryptococcal Meningitis Induction Therapy in sub-Saharan Africa: Study Protocol for a Phase 3 Randomised Controlled Non-Inferiority Trial

Duolao Wang, S. Jaffar, D. Boulware, 2019, Trials.

Induction OptimisatioN (AMBITION): High dose AmBisome for cryptococcal meningitis induction therapy in sub-Saharan Africa: economic evaluation protocol for a randomised controlled trial-based

Duolao Wang, S. Jaffar, D. Boulware, 2019 .